U.S. Biosimilars Market Size, Share and Industry Analysis By Drug Class (Filgrastim & Pegfilgrastim, Monoclonal Antibodies, Others), By Disease Indication (Cancer, Autoimmune Diseases, Others) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Regional Forecast, 2020 - 2029 (Includes COVID-19 Business Impact)

                                          
We have updated U.S. Biosimilars Market with respect to COVID-19 Business Impact.
Inquire before buying

This report focuses on the U.S. Biosimilars market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall U.S. Biosimilars market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.

Global U.S. Biosimilars Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.

Global U.S. Biosimilars Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.

Global U.S. Biosimilars Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

 	
Novartis AG
 	
Merck & Co.
 	
Coherus BioSciences, Inc.
 	
AbbVie Inc.
 	
Pfizer Inc.
 	
Hoffmann-La Roche Ltd.
 	
Eli Lilly and Company
 	
Teva Pharmaceutical Industries Ltd.
 	
Celltrion Inc.
 	
Amgen Inc.
 	
Other prominent players

Report Coverage

Biosimilars refers to the medical biologic product that is similar to another medical biologics product called as the reference product. Biosimilars possesses equal similarity with the reference product in terms of purity, safety, efficacy, and potency. But it may differ in clinically inactive components used. Though biosimilars are identical to the reference product; approval of biosimilars requires positive clinical study to prove its safety and efficacy in the treatment of concerned disease or condition. Biosimilars offer a cost-effective alternative to highly-priced branded drugs, which has become the primary reason for increased demand for biosimilars in the pharmaceutical and healthcare sector. The higher adoption of biosimilars for the treatment of diseases and reduced healthcare cost have also triggered drugs manufacturers to conduct research and launch new biosimilars in the market. Increased FDA approvals for biosimilars, increased research, patent expiry, and potential pipeline candidates are expected to positively impact the demand for biosimilars in the U.S.

The U.S. biosimilars market report provides qualitative and quantitative insights on industry trends and a detailed analysis of market size and growth rate for all possible segments in the market. The market is segmented by drug class, by disease indication, and by distribution channel. On the basis of the drug class, the U.S. biosimilars market segments include filgrastim & pegfilgrastim, monoclonal antibodies, and others. Based on disease indication, this market segments include cancer, autoimmune diseases, and others. The autoimmune diseases segment is further divided into arthritis, psoriasis, neutropenia, and others. Various distribution channels covered under the report are hospital pharmacy, retail pharmacy, and online pharmacy.
Along with this, the report on U.S. market analysis includes market dynamics and competitive landscape. Various key insights provided in the report are the prevalence of key diseases associate with the scope for key countries, new product launch, pipeline analysis, patent snapshot of biologics, the regulatory scenario in key countries, reimbursement scenario for key countries, recent industry developments such as mergers & acquisitions, and key industry trends.
SEGMENTATION

By Drug Class

 	
Filgrastim & Pegfilgrastim
 	
Monoclonal Antibodies
 	
Others

By Disease Indication

 	
Cancer
 	
Autoimmune Diseases
 	
Arthritis
 	
Psoriasis
 	
Neutropenia
 	
Others
 	
Others

By Distribution Channel

 	
Hospital Pharmacy
 	
Retail Pharmacy
 	
Online Pharmacy

Key Industry Developments

In July 2020, Accord Healthcare S.L.U. received marketing authorization valid throughout the European Union for Zercepac(trastuzumab). Zercepac can only be used when cancer overexpresses HER2: this means that cancer produces a protein called HER2 in large quantities on the cancer cells. HER2 is overexpressed in about a quarter of breast cancers and a fifth of gastric cancers.
Zercepac has a highly similar structure, purity, and biological activity to Herceptin and is distributed in the body in the same way. In addition, studies in metastatic breast cancer that overexpressed HER2 have shown that the effectiveness of Zercepac infusion is equivalent to that of Herceptin infusion.

In April 2019, Samsung Bioepis received FDA approval for ETICOVO, a biosimilar of Etanercept for the treatment of rheumatoid arthritis.

In March 2019, Pfizer received FDA approval for TRAZIMERA, a biosimilar of Trastuzumab for treating patients with breast cancer and gastroesophageal junction adenocarcinoma.
In July 2018, Pfizer received FDA approval for NIVESTYM, a biosimilar of Filgrastim for indications equal to that of reference product.

In November 2018, the FDA granted approval to Truxima, biosimilar of rituximab developed by Celltrion Inc. for the treatment of B-cell non-Hodgkins lymphoma.

&nbsp